NASDAQ:ONTX Onconova Therapeutics (ONTX) Stock Forecast, Price & News $1.20 +0.02 (+1.69%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.17▼$1.2250-Day Range$0.67▼$1.4252-Week Range$0.62▼$1.52Volume36,641 shsAverage Volume125,291 shsMarket Capitalization$25.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Onconova Therapeutics (NASDAQ:ONTX) StockOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.Read More Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Stock News HeadlinesMay 31, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Onconova Therapeutics (NASDAQ:ONTX)May 27, 2023 | americanbankingnews.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Short Interest UpdateJune 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 25, 2023 | finance.yahoo.comOnconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint BlockadeMay 24, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Onconova Therapeutics (NASDAQ:ONTX)May 20, 2023 | americanbankingnews.comOnconova Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.29) Per Share (NASDAQ:ONTX)May 19, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Onconova Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ONTX)May 17, 2023 | marketwatch.com8-K: Onconova Therapeutics, Inc.June 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Buy RecommendationMay 16, 2023 | markets.businessinsider.comOnconova Therapeutics (ONTX) Gets a Buy from Noble FinancialMay 16, 2023 | finanznachrichten.deOnconova Therapeutics, Inc.: Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)May 16, 2023 | finance.yahoo.comQ1 2023 Onconova Therapeutics Inc Earnings CallMay 15, 2023 | msn.comOnconova Therapeutics: Q1 Earnings InsightsMay 15, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue EstimatesMay 15, 2023 | investing.comOnconova Therapeutics (ONTX) Earnings Dates & ReportsMay 15, 2023 | finance.yahoo.comOnconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 14, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.comMay 12, 2023 | finance.yahoo.comOnconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 11, 2023 | finance.yahoo.comOnconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 8, 2023 | americanbankingnews.comOnconova Therapeutics (ONTX) to Release Earnings on MondayMay 8, 2023 | finance.yahoo.comOnconova Therapeutics to Present at the ISID International Epidermolysis Bullosa SymposiumMay 6, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Research Coverage Started at StockNews.comMay 4, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023April 21, 2023 | msn.comHC Wainwright & Co. Upgrades Onconova Therapeutics (ONTX)April 21, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Upgraded at HC WainwrightSee More Headlines ONTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONTX Company Calendar Last Earnings3/16/2023Today6/03/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-9,122.57% Pretax Margin-9,122.57% Return on Equity-67.03% Return on Assets-49.59% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.80 Sales & Book Value Annual Sales$230,000.00 Price / Sales109.41 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book1.10Miscellaneous Outstanding Shares20,970,000Free Float20,718,000Market Cap$25.16 million OptionableNot Optionable Beta1.78 Key ExecutivesSteven M. FruchtmanPresident, Chief Executive Officer & DirectorMark P. GuerinChief Operating & Financial OfficerMatthew ParrisVice President-Clinical OperationsMichael SaundersChief Medical OfficerAdar Makovski SilversteinSenior Director & Head-Corporate DevelopmentKey CompetitorsLipocineNASDAQ:LPCNMetacrineNASDAQ:MTCRCumberland PharmaceuticalsNASDAQ:CPIXCocrystal PharmaNASDAQ:COCPAcasti PharmaNASDAQ:ACSTView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 22,852 shares on 5/12/2023Ownership: 0.690%Simplex Trading LLCSold 100 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ONTX Stock - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. How have ONTX shares performed in 2023? Onconova Therapeutics' stock was trading at $0.6457 at the start of the year. Since then, ONTX shares have increased by 85.8% and is now trading at $1.20. View the best growth stocks for 2023 here. Are investors shorting Onconova Therapeutics? Onconova Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 291,400 shares, a drop of 24.8% from the April 30th total of 387,400 shares. Based on an average daily volume of 540,800 shares, the days-to-cover ratio is currently 0.5 days. View Onconova Therapeutics' Short Interest. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Thursday, March, 16th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.08 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 9,122.57%. When did Onconova Therapeutics' stock split? Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.69%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View institutional ownership trends. How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.20. How much money does Onconova Therapeutics make? Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $25.16 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681. This page (NASDAQ:ONTX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.